Edwards cited broader TAVR treatment populations and ongoing evidence generation as key growth drivers for the new year.

A steady stream of structural trial data, approvals, reimbursement decisions, and real-world rollouts arrived in 2025.

While the first innovators in the area of minimally invasive cardiac procedures began introducing methods such as finger-fracture valvuloplasty as early as the 1920s — in the case of England’s Henry ...

Please provide your email address to receive an email when new articles are posted on . Transcatheter aortic valve replacement for younger adults with severe aortic stenosis rose nearly ninefold from ...

RANCHO MIRAGE, Calif., Jan. 4, 2024 /PRNewswire/ -- Eisenhower Health is the first hospital in the United States to become an Edwards Benchmark program Case Observation Site for the treatment of ...

For the rising number of patients needing aortic reintervention, transcatheter aortic valve replacement (TAVR) explantation carried the highest mortality risk, two registry analyses affirmed. In ...

WASHINGTON, DC — Transcatheter aortic valve replacement (TAVR) is superior to surveillance in patients with severe but asymptomatic aortic stenosis with no apparent cost in adverse events, according ...

St. Luke’s Medical Center-Global City marks a significant milestone for its cardiovascular services, having successfully ...

Boston Scientific, Inc. BSX has obtained a CE Mark for the ACURATE Prime Aortic Valve System — the newest transcatheter aortic valve replacement (TAVR) technology in its structural heart portfolio.

Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under age 65 with severe aortic stenosis, many hospitals are still opting for a nonsurgical approach in ...

The Federal Trade Commission (FTC) has moved to block Edwards Lifesciences’ purchase of JenaValve Technology and its transcatheter heart valve implant for treating aortic regurgitation, which is ...